Bergenin

Bergenin

Bergenin is a naturally occurring polyphenolic C-glycoside found across a wide range of plant families and has been used for centuries in traditional medicine systems across South Asia and East Asia. Since its scientific isolation in the nineteenth century, it has attracted growing pharmacological interest for a broad spectrum of biological activities. The following article covers its chemical identity, botanical sources, traditional uses, mechanisms of action, pharmacological evidence, pharmacokinetics, formulation science, and safety data as documented in peer-reviewed literature.

1. Identity and Chemical Characterization

1.1 Nomenclature and Synonyms

Bergenin, also known as ardisic acid B, bergenit, bergenitol, cuscutin, peltophorin, and vakerin, is a C-glucoside of 4-O-methyl gallic acid (2β-d-glucopyranosyl 4-O-methyl gallic acid δ lactone). In chemical terms it is a glycoside of trihydroxybenzoic acid, and in particular the C-glycoside of 4-O-methyl gallic acid.

1.2 Chemical Structure and Physical Properties

Bergenin is a naturally occurring isocoumarin derivative, classified as a C-glucoside tannin. It appears as a white to off-white crystalline powder with a molecular formula of C₁₄H₁₆O₉ and a molecular weight of 328.27 g/mol, exhibiting solubility in water, ethanol, and methanol but limited solubility in non-polar solvents.

In IUPAC nomenclature bergenin bears the name (2R,3S,4S,4aR,10bS)-3,4,8,10-tetrahydroxy-2-(hydroxymethyl)-9-methoxy-3,4,4a,10b-tetrahydro-2H-pyran[3,2-c]isochromen-6-one. A distinguishing structural feature is that, unlike most glycosides, bergenin is a C-glucoside of 4-O-methyl gallic acid that is not hydrolyzed by glucosidases, conferring metabolic stability in the gut. The molecule carries five hydroxyl groups; bergenin is an isocoumarin derivative with five hydroxyl groups.

Key physicochemical and computed pharmacokinetic parameters are summarized in published SWISS ADME analyses: its molecular weight is 328.27 g/mol, it has nine hydrogen-bond acceptors, five hydrogen-bond donors, two rotatable bonds, low predicted GI absorption, and it is not predicted to be a blood-brain barrier permeant; it does not inhibit CYP1A2, CYP2C9, CYP2C19, or CYP3A4 according to these computational predictions, and it satisfies Lipinski criteria.

1.3 Key Derivatives

Bergenin has a derivative, O-demethylated, called norbergenin. Among bergenin analogues, norbergenin is the most important and potentially bioactive constituent. Acetylated variants, such as acetylbergenin, are obtained by treating bergenin with acetic anhydride, introducing acetyl groups at hydroxyl sites like C-11 to improve lipophilicity; these are often isolated from plant sources like Mallotus japonicus before modification. Additional natural acylated derivatives found in plants include 11-O-galloylbergenin, 11-O-syringylbergenin, 11-O-vanilloylbergenin, and demethoxybergenin, among others.

2. Botanical Sources and Natural Distribution

2.1 Discovery and Primary Sources

Bergenin is a glycosidic derivative of trihydroxybenzoic acid that was discovered in 1880 by Garreau and Machelart from the rhizomes of the medicinal plant Bergenia crassifolia (currently: Saxifraga crassifolia—Saxifragaceae), though it was later isolated from several other plant sources. Its name is derived from the ornamental and medicinal plant Bergenia crassifolia L., obtained from the rhizomes of this plant, which was originally distributed in the temperate regions of North-Central Asia, mainly in Russia; however, the bergenin molecule has since been found in several plant species distributed worldwide.

Although bergenin was first isolated from the rhizomes of Saxifraga (Bergenia) siberica in 1881, its structure was confirmed only in 1958. Bergenin gained importance in the scientific community only in the twenty-first century, when its pharmacological properties were gradually explored.

2.2 Taxonomic Breadth

Bergenin is distributed in many plant species — at least 112 species belonging to 34 families. To date, bergenin is mainly obtained by direct extraction from the rhizomes or roots of Ardisia japonica, A. crenata, Bergenia crassifolia, B. purpurascens, Rodgersia sambucifolia, and others; however, this process is limited by the low and unstable content of bergenin in these medicinal plants.

Selected plant sources and their reported bergenin yields are documented in the primary literature. Notable sources and approximate yields include: Ardisia japonica (Myrsinaceae, ~0.02% w/w), Bergenia ciliata (Saxifragaceae, ~0.08%), Shorea robusta (Dipterocarpaceae, ~0.075%), Bergenia cordifolia (Saxifragaceae, ~0.57%), Endopleura uchi (Humiriaceae, ~1.13%), Mallotus japonicus (Euphorbiaceae, ~1.95%), Rodgersia sambucifolia (Saxifragaceae, ~3.13%), Diospyros sanja-minika (Ebenaceae, ~3.64%), and Bergenia stracheyi (Saxifragaceae, ~2.04%).

The bioactive compound bergenin occurs naturally in the rhizomes and leaves of members belonging to the genus Bergenia — B. ligulata, B. ciliata, B. stracheyi, and B. crassifolia — and is also found in plants of other genera including Mallotus philippinensis and Corylopsis spicata. Bergenin has garnered growing interest in recent years because of its occurrence in food and medicinal plants, such as the Amazonian herb "uchi" (Endopleura uchi), whose fruit serves both as a food and a medicinal product.

2.3 Co-occurring Phytochemicals in Bergenia

Constituents of Bergenia species have been categorized into polyphenols, flavonoids, quinones, sterols, terpenes, tannins, lactones, and others. The major bioactive compounds include bergenin, (+)-catechin, gallic acid, β-sitosterol, catechin-7-O-β-d-glucoside, (+)-afzelechin, arbutin, 4-O-galloylbergenin, 11-O-galloylbergenin, caffeoylquinic acid, pashaanolactone, 3,11-di-O-galloylbergenin, bergapten, and various flavonoid glycosides.

3. Traditional and Historical Use

3.1 Ayurvedic Medicine (Indian Subcontinent)

Bergenia ligulata is an essential ingredient of the Ayurvedic formulation "Pashanbheda" (from Sanskrit: Paashan = rockstone, bheda = piercing), used as a kidney stone dissolver in the indigenous system of medicine. This drug has been listed in ancient Indian chronicles of medicine including the Charaka Samhita, Sushruta Samhita, and Ashtang-Hridaya.

Bergenia species are popularly known as "Pashanbheda" (stone-breaker), and due to their antilithiatic and diuretic activities, these species have been traditionally used for treating kidney and urinary bladder stones in the indigenous systems of medicine in India and China. The rhizomes, especially of B. ligulata, are used as main ingredients in various Ayurvedic and Unani formulations for the treatment of urolithiasis, haemorrhoids, stomach disorders, ophthalmia, heart diseases, chronic venereal diseases, boils and blisters, leucorrhoea, piles, arthritis, epilepsy, and pulmonary infections.

Ayurvedic preparations have used Bergenia species down the centuries to dissolve bladder and kidney stones and to treat piles, abnormal leucorrhea, and pulmonary infections. B. ligulata is reputedly known by numerous Sanskrit synonyms including "Pashana," "Ashmabhid," "Ashmabhed," "Asmaribheda," "Nagabhid," "Parwatbhed," "Upalbhedak," and "Shilabhed."

Bergenia ligulata, commonly known as Indian rhubarb or Paashaanbhed, is a perennial herb native to the Himalayan region and widely distributed in the alpine regions of India, Nepal, and Bhutan, belonging to the family Saxifragaceae. Traditionally, various parts of Bergenia ligulata have been used in Ayurveda, traditional Chinese medicine, and folk medicine systems for their medicinal properties.

3.2 Traditional Chinese Medicine

These chemical compounds are used as drugs in Ayurveda medicine, commonly known as Paashaanbhed. Ardisia japonica (Zhusha Gen in Chinese medicine) is a primary source of bergenin in the Chinese pharmacopoeia tradition, where it has been employed in the management of respiratory ailments including chronic cough and tuberculosis. Bergenin monohydrate is the main medicinal component of Ardisia japonica, and a large number of studies have shown that Ardisia japonica can be employed clinically to treat lung injury diseases, such as tuberculosis.

3.3 Traditional Preparations

Across these traditions, the plant material — predominantly rhizomes — was prepared as decoctions, powders (churna in Ayurveda), and pastes. Traditionally, these species from the Saxifragaceae family were used to treat kidney stones, respiratory ailments, inflammation, and oxidative stress-related disorders. In Andean and Amazonian traditions, Endopleura uchi (uchi) fruit has served both as a food source and a medicinal product, constituting one of the richest known natural sources of bergenin.

4. Key Constituents, Biosynthesis, and Active Mechanisms

4.1 Biosynthetic Origin

The chemical synthesis of bergenin faces many challenges, especially in terms of regio- and/or stereoselective C-sugar and O-methyl group introduction. In recent years, exciting progress has been made in the production of medicinal natural products through synthetic biology; synthetic biology may address the resource shortage of bergenin. Although bergenin has been isolated for nearly 100 years, its biosynthetic pathway remained unclear until recently.

4.2 Anti-Inflammatory Mechanisms

Bergenin plays an anti-inflammatory role via the modulation of MAPK and NF-κB signaling pathways, as demonstrated in a mouse model of LPS-induced mastitis. More specifically, the intracellular signaling molecules including p38, ERK, JNK, IκB, and NF-κB-p65 are involved, and bergenin monohydrate executes its effects via the classical MAPK signaling pathway and NF-κB pathway.

Bergenin attenuates inflammation by down-regulating tumor necrosis factor alpha (TNF-α), interleukin-1 beta (IL-1β), myeloperoxidase, and cyclooxygenase-2 (COX-2), and mechanistically suppresses NF-κB nuclear translocation and phosphorylation of p38 mitogen-activated protein kinase.

Bergenin suppresses the release of reactive oxygen species (ROS), decreases the expression of inflammatory markers, and hinders apoptosis and autophagy. In bergenin pre-treatment groups, the expression of PPAR-γ-related genes is enhanced, while phosphorylation of P38 MAPK, NF-κB p65, and JAK2/STAT1-related proteins is reduced in a dosage-dependent manner.

4.3 Antioxidant Mechanisms

The hepatoprotective and neuroprotective activities of bergenin were reported to be mediated through its free radical scavenging property in both in vitro and in vivo models. In addition to increasing glutathione activity, the antioxidant capacity to eliminate ROS also triggers activation of the Peroxisome Proliferator-Activated Receptor γ (PPARγ), which regulates many proinflammatory cytokines. Bergenin markedly up-regulates protein expression of SIRT1, which regulates inflammation and redox status; it also improves expression of the major antioxidant transcription factor Nrf2 and its responsive gene products heme oxygenase-1 and NAD(P)H quinone dehydrogenase 1.

4.4 Immunomodulatory Mechanisms

In cyclophosphamide-induced immunosuppressed mice, bergenin alleviated spleen and thymus injury, enhanced humoral immune function by increasing IgM and IgG serum levels, and enhanced cellular immune function. Bergenin induces Th1 immune responses and potently inhibits bacillary growth in a murine model of Mycobacterium tuberculosis infection by activating the MAP kinase and ERK pathways; the mechanism of immunomodulatory action appears to involve NF-κB and MAPK pathways.

4.5 Anticancer Mechanisms

Bergenin efficiently inhibits the proliferation of human cancer cells by stimulating the production of intracellular reactive oxygen species (ROS), causing DNA damage and leading to cell cycle arrest in the G1/G2 phases by blocking cell signaling pathways. Several studies have demonstrated that bergenin can induce cell cycle arrest and enhance apoptosis in human prostate cancer cell lines and murine breast cancer cell lines. Bergenin is also described as a powerful anti-angiogenic substance, decreasing the levels of essential angiogenic proteins such as Galectin 3 and MMP-9 in cervical cancer cells.

4.6 Antidiabetic Mechanisms

Protein tyrosine phosphatase-1B (PTP1B) is an intriguing target for anticancer and antidiabetic drugs; bergenin is found to inhibit human protein tyrosine phosphatase-1B (hPTP1B) in vitro. Among additional antidiabetic mechanisms reported for Bergenia-derived extracts is inhibition of α-glucosidase, an enzyme central to postprandial glucose absorption. One study showed for the first time that bergenin protected beta cells from cytokine-induced apoptosis and restored insulin secretory function by virtue of its anti-inflammatory, antioxidant, and anti-apoptotic properties.

4.7 Neuroprotective Mechanisms

Bergenin possesses efficacious antioxidant, antiulcerogenic, anti-HIV, hepatoprotective, neuroprotective, anti-inflammatory, and immunomodulatory activity. Previous studies have shown that bergenin has in vitro bovine adrenal tyrosine hydroxylase inhibitory activity, mushroom tyrosinase inhibitory activities, β-secretase (BACE-1) enzyme inhibitory activity, and has prevented neuronal death in the primary culture of rat cortical neurons. Bergenin protected HT22 (murine neuronal) cells from glutamate-induced cell death, with protection attributed to restoration of glutathione levels.

5. Scientific Evidence by Area of Use

The following sections describe the available evidence. The overwhelming majority of studies are preclinical (in vitro cell culture or animal models). Human clinical trial data for bergenin as an isolated compound is currently absent from the published literature. Evidence is therefore rated accordingly.

5.1 Inflammation and Pain

Evidence level: Preclinical (animal and in vitro); no human clinical trials identified.

A botanical lead extract standardized to bergenin (IIIM-160, derived from Bergenia ciliata) displayed inhibition of lipopolysaccharide-induced production of proinflammatory cytokines in THP-1 cells, with selectivity toward interleukin-6 (IL-6), and showed anti-inflammatory, anti-arthritic, and antinociceptive activity in animal models.

In a Balb/c mouse model, increasing doses of bergenin extracted from the rhizomes of B. stracheyi exhibited anti-arthritic properties in a dose-dependent manner up to a dose of 40 mg/kg, while a higher dose of 80 mg/kg caused a reduction in this activity.

In Klebsiella-infected mice, a specific dose of bergenin monohydrate effectively ameliorated lung injury and suppressed inflammatory cytokines such as TNF-α, IL-6, IL-1β, and PGE2, while also reducing myeloperoxidase and malondialdehyde levels and increasing SOD and GSH activities.

Bergenin and its derivatives were investigated for their role in down-regulating the expression of NF-κB and IKK-β in THP-1 cells, holding the promise of being antiarthritic drugs. In a 2024 Scientific Reports study, bergenin was shown to protect against osteoarthritis in experimental models by inhibiting STAT3, NF-κB, and Jun pathways and suppressing osteoclastogenesis. Bergenin prodrugs — notably acetyl ester 4a2 — may also be potential therapies against rheumatoid arthritis; studies showed that bergenin and its natural derivatives are not significantly cytotoxic and do not produce harmful side effects, which demonstrates potential for clinical applications.

5.2 Hepatoprotection

Evidence level: Preclinical (animal and in vitro); no human clinical trials identified.

Bergenin and gallic acid strengthened the physical structure of cells, increased cell survival, reduced lactate dehydrogenase (LDH) toxicity, restored aspartate aminotransferase (AST), alanine transaminase (ALT), and malondialdehyde (MDA) levels, stimulated SOD and CAT activities, and improved GSH content of HepG2 cells treated with ethanol and TBHP; bergenin demonstrated hepatoprotective action by restoring the oxidant-antioxidant system.

In iron-intoxicated rats, bergenin significantly decreased hepatic iron content, improved hepatocellular integrity as demonstrated by reduced intracellular liver enzyme activity, alleviated iron-induced histopathological anomalies, and improved the antioxidant potential of the liver tissue, as reflected by decreased DNA oxidative damage and lipid peroxidation.

5.3 Diabetes and Metabolic Disease

Evidence level: Preclinical (animal and in vitro); no human clinical trials identified.

Bergenin has demonstrated antidiabetic activity via multiple mechanisms in preclinical models. One key study showed for the first time that bergenin protected pancreatic beta cells from cytokine-induced apoptosis and restored insulin secretory function by virtue of its anti-inflammatory, antioxidant, and anti-apoptotic properties. Alpha-glucosidase inhibition, which slows postprandial glucose absorption, has also been documented in Bergenia extracts rich in bergenin.

5.4 Diabetic Neuropathy

Evidence level: Preclinical (animal model); no human clinical trials identified.

Bergenin was investigated in a mouse (C57/BL6) model of streptozotocin-induced painful diabetic neuropathy. Nociceptive thresholds were assessed by the von Frey test, and cytokines, antioxidant genes, and oxidative stress markers were measured in nervous tissues. Single (3.125–25 mg/kg) or multiple (25 mg/kg; twice a day for 14 days) treatments with bergenin reduced the behavioral signs of diabetic neuropathy in mice.

Bergenin reduced both nitric oxide production in vitro and malondialdehyde/nitrite amounts in vivo; these antioxidant properties were attributed to the modulation of gene expression by the downregulation of inducible nitric oxide synthase (iNOS) and upregulation of glutathione peroxidase and Nrf2 in the nervous system.

5.5 Neuroprotection and Neurodegeneration

Evidence level: Preclinical (in vitro and animal models); no human clinical trials identified.

Administration of bergenin to sodium azide-treated rats significantly recovered cognition and related biochemical variations; co-administration of Bisphenol A diglycidyl ether (BADGE), a PPAR-γ antagonist, challenged these neuroprotective effects. The findings suggest that the cognitive restoration potential of bergenin may be attributed to its modulatory effects against cholinesterase, oxidative stress, and inflammatory markers, as well as its neuroprotective actions, thus aligning it as a possible therapy for Alzheimer's disease-related dementia, with significance attributed to PPAR-γ receptors.

Bergenin pre-treatment leads to a significant reduction of lipid peroxidation in the liver, brain, and red blood cells of rats against 2,4-dinitrophenyl hydrazine-induced tissue damage. Various analogs of bergenin have demonstrated dose-dependent BACE-1 inhibitory activity, antioxidant activity, and in vitro tyrosinase inhibitory activity.

5.6 Urolithiasis (Kidney and Bladder Stones)

Evidence level: Preclinical (animal models); no human clinical trials identified for isolated bergenin.

The active component bergenin isolated from the rhizomes of B. ligulata has been shown to ameliorate renal dysfunction in hyperoxaluric rats by inhibiting the growth of calcium oxalate crystals. The proposed mechanisms of anti-urolithic activity include diuretic, antispasmodic, and antioxidant effects, as well as inhibitory effects on crystal nucleation and aggregation. This activity forms the scientific basis for the long-standing traditional use of Bergenia as "Pashanbheda" (stone-breaker).

5.7 Anticancer Activity

Evidence level: Preclinical (in vitro and limited animal models); no human clinical trials identified.

More preclinical and clinical investigations are needed to validate the candidature of bergenin as a potent anticancer agent. The in vitro evidence to date encompasses multiple cancer cell lines. Several studies have demonstrated that bergenin can induce cell cycle arrest and enhance apoptosis in human prostate cancer cell lines and murine breast cancer cell lines.

Fourteen bergenin/cinnamic acid hybrids were synthesized, characterized, and evaluated for antitumor activity both in vitro and in vivo; the most potent compound arrested HepG2 cells (IC₅₀ = 4.23 ± 0.79 μM) in the G2/M phase and induced cellular apoptosis.

5.8 Antiviral Activity (Including Anti-HIV)

Evidence level: Preclinical (in vitro); no human clinical trials identified.

Bergenin exhibits antihepatotoxic, antiulcerogenic, anti-HIV, antifungal, hepatoprotective, antiarrhythmic, neuroprotective, anti-inflammatory, immunomodulatory, and burn wound healing properties. Anti-HIV activity has been documented in vitro, but no clinical trials have been conducted with bergenin for this indication.

5.9 Antiulcer Activity

Evidence level: Preclinical (animal models); no human clinical trials identified.

Bergenin has demonstrated protection against pylorus-ligated gastric ulcers and gastric ulcers induced by aspirin, as well as cold restraint stress-induced ulcers in guinea pigs and rats in preclinical studies. Bergenin alone possesses burn-wound healing, antiulcer, anti-arrhythmic, antihepatotoxic, neuroprotective, antifungal, antidiabetic, antilithiatic, anti-inflammatory, anti-nociceptive, anti-HIV, and immunomodulatory properties.

5.10 Cardiac Effects (Antiarrhythmic)

Evidence level: Preclinical; no human clinical trials identified.

Antiarrhythmic effects of bergenin have been documented in preclinical models and are consistently listed as a recognized pharmacological property across multiple review articles. The mechanism underlying this activity is not fully elucidated at the molecular level in currently available human data.

5.11 Antimalarial and Antiparasitic Activity

Evidence level: Preclinical (in vitro and animal models); no human clinical trials identified.

Bergenin has shown potential antimalarial, antileishmanial, and trypanocidal activities in preclinical models. These findings are preliminary and have not been translated into clinical investigation.

6. Body Systems Associated with Bergenin Activity

• Musculoskeletal system: Anti-arthritic and antinociceptive effects in animal models, including osteoarthritis and rheumatoid arthritis models.
• Hepatic system: Hepatoprotective effects against toxic and oxidative insults in multiple preclinical models.
• Renal and urinary system: Traditional antilithiatic (kidney stone-dissolving) and diuretic use, supported by animal data on calcium oxalate crystal inhibition.
• Immune system: Immunomodulatory effects including promotion of humoral and cellular immunity, particularly in immunosuppression models.
• Nervous system: Neuroprotective effects against oxidative neuronal injury, BACE-1 inhibition, and cognitive rescue in dementia animal models.
• Endocrine/metabolic system: Antidiabetic effects via beta-cell protection, α-glucosidase inhibition, and PTP1B inhibition in preclinical settings.
• Gastrointestinal system: Antiulcer and cytoprotective effects documented in animal gastric models.
• Cardiovascular system: Antiarrhythmic and cardioprotective effects reported in preclinical literature.
• Respiratory system: Traditional use for cough (antitussive) and pulmonary infections, with some supporting in vivo data for lung protection.

7. Pharmacokinetics and Bioavailability

7.1 Absorption

Bergenin is classified as a Biopharmaceutics Classification System class IV (BCS IV) drug with poor hydrophilicity and lipophilicity, and is potentially eliminated by the efflux function of P-glycoprotein (P-gp); these factors explain its low oral bioavailability.

Human intestine absorption (HIA) is a measure of oral bioavailability, and it is evident that bergenin exhibits inadequate human intestine absorption of less than 30%. The anticipated Caco-2 permeability of bergenin is −6.191 log cm/s, measured at less than −5.15 log cm/s, indicating poor Caco-2 permeability.

7.2 Oral Bioavailability and Half-Life

Following a single oral gavage administration of bergenin to male Sprague-Dawley rats at 50 mg/kg, the median time to reach maximum plasma concentration was 0.25 hours, with a peak plasma concentration (Cmax) of 170 ng/mL. Plasma exposure (AUClast) was 269 h·ng/mL. The terminal plasma half-life was 1.74 hours, and the absolute oral bioavailability of bergenin was determined to be 3%.

Bergenin undergoes degradation at intestinal pH (pH 6.8 and above), with a degradation half-life at pH 7 and pH 8 of 14.4 and 2.9 hours, respectively. In pharmacokinetic studies in rats, the plasma half-life of bergenin is low at 1–3 hours.

Following oral ingestion in humans, bergenin is rapidly but partially absorbed, exhibiting a brief half-life and limited bioavailability. The clearance value of bergenin is reported to be 8.395 mL/min/kg, indicating a high clearance rate.

7.3 P-Glycoprotein Interactions

Bergenin is a highly effective inhibitor of P-glycoprotein. The modulation of P-glycoprotein-mediated transport has considerable pharmacokinetic consequences for P-glycoprotein substrates, which may be utilized for particular therapeutic benefits or lead to contraindications. Bergenin also possesses a high likelihood of being employed as a P-glycoprotein substrate.

7.4 Blood-Brain Barrier

Bergenin possesses only modest blood-brain barrier (BBB) permeability, hence restricting its efficacy for central nervous system (CNS) illnesses. This contrasts with evidence of neuroprotective activity, which may occur through peripheral mechanisms or under conditions where the BBB is compromised.

8. Dosage Forms and Reported Dosages

8.1 Conventional Forms

Bergenin is available in its natural plant matrix as dried rhizome powder, standardized plant extracts (hydroalcoholic), decoctions, and as isolated purified compound. In research settings, it is used as a crystalline powder or dissolved in dimethyl sulfoxide (DMSO) or aqueous vehicle for in vitro assays.

8.2 Dosages Reported in Preclinical Studies

The following dosages appear in published preclinical research and are provided solely as scientific reference data:

• Single doses of 3.125–25 mg/kg or multiple doses of 25 mg/kg twice daily for 14 days were used in a mouse model of diabetic neuropathy.
• Doses of up to 40 mg/kg showed anti-arthritic activity in Balb/c mice, while 80 mg/kg showed a reduction in activity.
• Bergenin-standardized extract (IIIM-160) was not toxic at oral doses up to 2 g/kg in Swiss-albino mice.

8.3 Novel Drug Delivery Systems

The low oral bioavailability of bergenin has driven significant pharmaceutical research into enhanced formulations. A gastroretentive, sustained-release capsule formulation showed sustained release of bergenin over a period of 24 hours, resulting in improved plasma exposure in Sprague-Dawley rats. Pharmacokinetic results indicated a 4-fold increase in the AUClast of bergenin in a gastroretentive sustained-release (GRSR) formulation compared to plain extract; Tmax, t½, and Tlast values were also increased due to sustained release.

The relative oral bioavailability of a bergenin-phospholipid complex solid dispersion (BNPC-SD) was 156.33%, and when co-administered with the P-gp inhibitor verapamil it reached 202.46%, compared with bergenin given alone, confirming that this approach can increase oral bioavailability of BCS IV drugs.

Bergenin-loaded Eudragit® L100 (EL100) polymeric nanoparticles were fabricated via nanoprecipitation; an experimental design was conducted for optimization. The optimized nanoformulation had a mean particle size of 86.17 ± 2.1 nm, a zeta potential of −32.33 ± 5.53 mV, and a polydispersity index of 0.30 ± 0.03.

9. Safety Considerations

9.1 Acute Toxicity

Bergenin showed anti-inflammatory, anti-arthritic, and antinociceptive activity in animal models and was not toxic at oral doses up to 2 g/kg in Swiss-albino mice. Both bergenin derivatives (natural and semisynthetic) and extracts with phytochemical proof of their highest concentration are well studied, and none of the studies showed cytotoxicity for healthy cells.

Because of the few side effects, low toxicity, and lack of drug resistance of bergenin, structural modifications and biological activity research have been conducted by medicinal chemists.

9.2 Pharmacokinetic-Based Safety Considerations

Bergenin is a highly effective inhibitor of P-glycoprotein; the modulation of P-glycoprotein-mediated transport has considerable pharmacokinetic consequences for P-glycoprotein substrates, which may lead to contraindications. This means bergenin may potentially alter the absorption, distribution, or elimination of co-administered drugs that are P-gp substrates — a clinically relevant consideration that warrants attention in future studies, though human interaction data are not yet available.

Computational profiling indicates that bergenin does not inhibit CYP1A2, CYP2C9, CYP2C19, or CYP3A4, suggesting a low liability for cytochrome P450-mediated drug interactions, though these are in silico predictions and have not been confirmed in human subjects.

9.3 Intestinal Stability

Bergenin undergoes degradation at intestinal pH (pH 6.8 and above), with a degradation half-life at pH 7 and pH 8 of 14.4 and 2.9 hours, respectively. This instability at higher gut pH values contributes to poor and variable oral bioavailability and is a key driver for the development of enteric and gastroretentive formulations.

9.4 Absence of Human Clinical Data

A critical limitation of the entire bergenin evidence base is the complete absence of published human clinical trials evaluating isolated bergenin as a therapeutic or supplementary agent. All efficacy and most safety data derive from in vitro cell studies and animal experiments. Extrapolation of animal dosages to human dosages is not scientifically validated for this compound, and the pharmacokinetics observed in rodents may differ substantially from human pharmacokinetics. More comprehensive reviews are needed on the pharmacological properties of bergenin.

10. Current Research Directions

Researchers must concentrate not only on the efficacy of bergenin, which is of significant interest, but also on drug delivery systems capable of addressing pharmacokinetic challenges, as well as investigating derivatives with enhanced biological activity.

Major active research areas include: development of nanoparticle and phospholipid complex formulations to overcome low bioavailability; synthesis of semi-synthetic derivatives (such as cinnamic acid hybrids and acylated bergenin esters) with improved potency and selectivity; biosynthetic pathway elucidation via synthetic biology for scalable production; and application of network pharmacology and molecular docking to identify novel targets. Researchers aim to leverage the multifaceted benefits of bergenin to formulate safer and novel cancer therapies, while establishing a robust framework for future investigations, with acknowledgment that more preclinical and clinical investigations are needed.

References

• Moraes et al. (2023). Chemistry and Pharmacology of Bergenin or Its Derivatives: A Promising Molecule. Biomolecules, 13(3), 403. PMC10046151.
• Mehmood et al. (2024). Bergenin, a bioactive flavonoid: advancements in the prospects of anticancer mechanism, pharmacokinetics and nanoformulations. Frontiers in Pharmacology. PMC11743450.
• Ahmad et al. (2020). Bergenia Genus: Traditional Uses, Phytochemistry and Pharmacology. Molecules, 25(23), 5555. PMC7730924.
• Nature Communications (2024). Unravelling and reconstructing the biosynthetic pathway of bergenin.
• ScienceDirect Topics. Bergenin — Overview.
• Qi et al. (2018). Protective Effect of Bergenin against Cyclophosphamide-Induced Immunosuppression by Immunomodulatory Effect and Antioxidation in Balb/c Mice. PMC6222609.
• Scientific Reports (2024). Bergenin protects against osteoarthritis by inhibiting STAT3, NF-κB and Jun pathways and suppressing osteoclastogenesis.
• ScienceDirect (2022). Cross-talk between PPARγ, NF-κB, and p38 MAPK signaling mediates the ameliorating effects of bergenin against iron overload-induced hepatotoxicity.
• PMC (2021). Bergenin Monohydrate Attenuates Inflammatory Response via MAPK and NF-κB Pathways Against Klebsiella pneumonia Infection. PMC8129520.
• PMC (2020). Bergenin Reduces Experimental Painful Diabetic Neuropathy by Restoring Redox and Immune Homeostasis in the Nervous System. PMC7420298.
• PMC (2020). Bergenin protects pancreatic beta cells against cytokine-induced apoptosis in INS-1E cells. PMC7751853.
• PMC (2022). Bergenin ameliorates cognitive deficits and neuropathological alterations in sodium azide-induced experimental dementia. PMC9556967.
• AAPS PharmSciTech (2018). Evaluation of Intestinal Absorption and Bioavailability of a Bergenin–Phospholipid Complex Solid Dispersion in Rats.
• ScienceDirect (2016). Comparative pharmacokinetics of bergenin, a main active constituent of Saxifraga stolonifera Curt., in normal and hepatic injury rats.
• PMC (2022). Design and Evaluation of pH-Sensitive Nanoformulation of Bergenin Isolated from Bergenia ciliata. PMC9104231.
• Fitoterapia (2015). Diversity, pharmacology and synthesis of bergenin and its derivatives: Potential materials for therapeutic usages.
• ScienceDirect (2018). Neuroprotective effects of bergenin in Alzheimer's disease: Investigation through molecular docking, in vitro and in vivo studies.
• PMC (2017). Major bioactive phenolics in Bergenia species from the Indian Himalayan region. PMC5531703.
• Frontiers in Pharmacology (2024). Bergenin, a bioactive flavonoid: advancements in the prospects of anticancer mechanism, pharmacokinetics and nanoformulations.
• MDPI Pharmacoepidemiology (2022). A Fresh Look on Bergenin: Vision of Its Novel Drug Delivery Systems and Pharmacological Activities.
• Encyclopedia MDPI (2021). Bergenia Genus.